Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.40USD
19 Aug 2017
Change (% chg)

$0.02 (+4.17%)
Prev Close
$0.38
Open
$0.38
Day's High
$0.41
Day's Low
$0.36
Volume
87,847
Avg. Vol
311,178
52-wk High
$2.64
52-wk Low
$0.30

HEB

Chart for HEB

About

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development... (more)
No analyst recommendations are available for HEB.

Overall

Beta: -0.82
Market Cap(Mil.): $11.67
Shares Outstanding(Mil.): 29.17
Dividend: --
Yield (%): --

Financials

  HEB Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -0.37 -- --
ROI: -58.66 2.83 14.89
ROE: -65.05 5.09 16.13

BRIEF-Hemispherx Biopharma announces corporate progress and financial results for the 6 months ended June 30 '17

* Hemispherx Biopharma announces corporate progress and financial results for the six months ended June 30, 2017

Aug 15 2017

BRIEF-Hemispherx Biopharma updates on study of Ampligen

* Hemispherx human safety study of intranasal Ampligen with influenza vaccine shows Ampligen was generally well-tolerated ‍​

Aug 14 2017

BRIEF-Hemispherx Biopharma updates status of immuno-oncology program in pancreatic cancer

* Hemispherx updates status of immuno-oncology program in pancreatic cancer

Jul 10 2017

BRIEF-Hemispherx Biopharma announces quarterly loss per share $0.11

* Hemispherx Biopharma announces financial results for the three months ended March 31, 2017

May 15 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.80 -0.85
Pfizer Inc. (PFE.N) $32.67 -0.28
Merck & Co., Inc. (MRK.N) $61.49 -0.32
GlaxoSmithKline plc (GSK.L) 1,490.00 -16.00
AstraZeneca plc (AZN.L) 4,447.00 -34.00
Baxter International Inc (BAX.N) $60.87 +0.05
MediGene AG (MDG1k.DE) €9.09 -0.03

Earnings vs. Estimates